标准短程方案与个体化长程方案治疗耐利福平/耐多药结核病的比较
该研究比较了WHO推荐的9-12个月标准短程方案与≥20个月个体化长程方案治疗耐利福平或耐多药结核病的效果。通过倾向性评分匹配的混合效应元回归分析发现,短程方案治疗成功率更高(80.0% vs 75.3%),主要因失访更少(aRD -0.15),但失败或复发风险略高(aRD 0.02),且在基线对吡嗪酰胺、丙硫异烟胺/乙硫异烟胺或乙胺丁醇耐药时风险更高。
要点
- 符合WHO短程方案使用标准的患者中,短程方案失访显著少于长程方案。
- 短程方案总体失败或复发风险略高,对组分药物耐药时风险进一步增加。
- 研究支持改善可靠药敏试验的可及性以指导方案选择。
核心结论
- 在符合WHO短程方案使用标准的患者中,标准短程方案较个体化长程方案失访更少,但失败或复发风险略高,尤其对组分药物耐药时。
主要发现
- 短程方案治疗成功率80.0%,长程方案75.3%。
- 短程方案失访调整风险差aRD -0.15(95%CI -0.17~-0.12)。
- 短程方案失败或复发总体aRD 0.02(95%CI 0~0.05)。
- 基线吡嗪酰胺耐药时失败或复发aRD 0.12(95%CI 0.07~0.16)。
- 基线丙硫异烟胺/乙硫异烟胺耐药时aRD 0.07(95%CI -0.01~0.16),乙胺丁醇耐药时aRD 0.09(95%CI 0.04~0.13)。
关键数值与推荐
- 短程方案使用标准:既往未使用二线药物,且耐利福平/耐多药结核对氟喹诺酮类和二线注射剂敏感。
临床怎么用
- 对符合WHO标准的患者可优先考虑短程方案以减少失访,但需警惕组分药物耐药导致的失败或复发风险。
- 应完善药敏试验以排除对短程方案组分药物的耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9-12 months (the "shorter regimen") and individualised regimens of ≥20 months ("longer regimens").We collected individual patient data from observational studies identified through systematic reviews and a public call for data. We included patients meeting WHO eligibility criteria for the shorter regimen: not previously treated with second-line drugs, and with fluoroquinolone- and second-line injectable agent-susceptible RR/MDR-TB. We used propensity score matched, mixed effects meta-regression to calculate adjusted odds ratios and adjusted risk differences (aRDs) for failure or relapse, death within 12 months of treatment initiation and loss to follow-up.We included 2625 out of 3378 (77.7%) individuals from nine studies of shorter regimens and 2717 out of 13 104 (20.7%) individuals from 53 studies of longer regimens. Treatment success was higher with the shorter regimen than with longer regimens (pooled proportions 80.0% versus 75.3%), due to less loss to follow-up with the former (aRD -0.15, 95% CI -0.17- -0.12). The risk difference for failure or relapse was slightly higher with the shorter regimen overall (aRD 0.02, 95% CI 0-0.05) and greater in magnitude with baseline resistance to pyrazinamide (aRD 0.12, 95% CI 0.07-0.16), prothionamide/ethionamide (aRD 0.07, 95% CI -0.01-0.16) or ethambutol (aRD 0.09, 95% CI 0.04-0.13).In patients meeting WHO criteria for its use, the standardised shorter regimen was associated with substantially less loss to follow-up during treatment compared with individualised longer regimens and with more failure or relapse in the presence of resistance to component medications. Our findings support the need to improve access to reliable drug susceptibility testing.
引用
- Abidi S, Achar J, Assao Neino MM, et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J. 2020. PMID: 31862767. doi:10.1183/13993003.01467-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。